Lisa Takagi

Lisa Takagi

Managing Editor

Tokyo, Japan

Lisa provides editorial coverage of all aspects of Japan’s prescription drug market for Scrip and Pink Sheet, including company, market, pricing and regulatory developments, as well as publishing podcast content regularly in the local Japanese language. Lisa brings close to a decade of experience working in either international teams or reporting, writing and editing, including in broadcast media through an internship as a TV reporter in Canada. Most recently, she covered the IT sector for ITmedia Enterprise in Japan. Lisa is bilingual in Japanese and English. She speaks basic French and Mandarin with keen interests in learning new languages. She holds an MA in Fine Art from Tokyo University of the Arts as well as a Master’s in Journalism from the University of King’s College in Halifax, Canada.

Latest from Lisa Takagi

Leqembi Facing 15% Price Cut In Japan

Japan looks set to press ahead with a reimbursement price cut for Eisai's Alzheimer's drug Leqembi following a cost-effectiveness review, despite differences with the company over methodology.

China Sentences Astellas Employee To 3.5 Years In Prison On Spy Charges

An employee of Astellas faces three and a half years in prison after sentencing by a court in China on espionage charges.

Activist Investor Vs. Japan Pharma: ASKA Plans Poison Pill As Dalton Pushes For MBO

While ASKA plans to dilute the holding of largest investor Dalton by issuing new shares, the US investment firm continues to push a management buyout option to the mid-sized Japanese pharma company.

Asia Deal Watch: JCR And Alexion Build Upon Existing Gene Therapy Alliances

Plus deals involving TandemAI/Perpetual Medicines, Biocytogen/BeOne, Chugai/Gero, CStone/Istituto Gentili, Alembic/Utility, Brii/Joincare, HanchorBio/Henlius, Rakuten/Cyntec and more.

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

Beyond AI Hype: Tokyo-1’s Real Answer On How To Innovate Pharma R&D

Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.